Considering that HSF1, HSF2, and HSF4 display multiple properties in cancer, which are either unique or common for each factor, or whether they act synergistically or antagonistically with each other, the need for new and improved agents targeting HSFs is significant. This evidence concerns the gene HSF2 and cancer.